Search Results

ZOLL Receives Innovative Technology Contract from Vizient for TherOx SuperSaturated Oxygen (SSO 2 ) Therapy.

ZOLL, an Asahi Kasei company, announced today that the first patient has enrolled in the REAL SSO2 post-market observational study to assess the clinical utility and cost-effectiveness of TherOx SuperSaturated Oxygen (SSO2) Therapy compared to PCI alone in standard of care treatment for ST-elevation myocardial infarction (STEMI) patients.

ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that its TherOx SuperSaturated Oxygen (SSO2) Therapy has been awarded a group purchasing agreement for Diagnostic and Interventional Cardiology Catheters (DIC) with Premier, Inc., effective as of July 1, 2022.

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that the Centers for Medicare & Medicaid Services ICD-10 Coordination and Maintenance Committee has issued a new ICD-10-PCS code for TherOx® SuperSaturated Oxygen Therapy.

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its TherOx® SuperSaturated Oxygen Therapy will be highlighted at the upcoming Transcatheter Cardiovascular Therapeutics annual scientific meeting November 4-6 in Orlando, Florida.

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its TherOx® SuperSaturated Oxygen (SSO2) Therapy will be the focus of a panel discussion at the upcoming Society for Cardiovascular Angiography & Interventions (SCAI) Shock virtual conference October 7-8.

TherOx announces key data presentations and company-sponsored events for SuperSaturated Oxygen (SSO2) Therapy at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium Sept. 25-29 at the Moscone Center in San Francisco.

March 30, 2020 13:23 UTC FDA Approves Next-Generation ZOLL ® TherOx System for Widowmaker Heart Attack Patients First and Only Treatment to Reduce Heart Muscle Damage Following Angioplasty and Stenting CHELMSFORD, Mass.--( BUSINESS WIRE )-- ZOLL ® Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions, announced today it has received U.S. Food and Drug Administration (FDA) approval of the second-generation Ther

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the first patient has enrolled in the AMIHOT III post-approval study further evaluating TherOx® SuperSaturated Oxygen (SSO2) Therapy for the treatment of the most severe form of heart attack, left anterior descending (LAD) ST-Elevation Myocardial Infarction (STEMI).